RU2008147737A - ANTUBERCULOSIS DRUG AND METHOD FOR ITS PRODUCTION - Google Patents
ANTUBERCULOSIS DRUG AND METHOD FOR ITS PRODUCTION Download PDFInfo
- Publication number
- RU2008147737A RU2008147737A RU2008147737/15A RU2008147737A RU2008147737A RU 2008147737 A RU2008147737 A RU 2008147737A RU 2008147737/15 A RU2008147737/15 A RU 2008147737/15A RU 2008147737 A RU2008147737 A RU 2008147737A RU 2008147737 A RU2008147737 A RU 2008147737A
- Authority
- RU
- Russia
- Prior art keywords
- tuberculosis drug
- tuberculosis
- protionamide
- rifabutin
- pyrazinamide
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000000814 tuberculostatic agent Substances 0.000 claims abstract 10
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 claims abstract 8
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims abstract 4
- ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 claims abstract 4
- 239000000796 flavoring agent Substances 0.000 claims abstract 4
- 235000019634 flavors Nutrition 0.000 claims abstract 4
- 229960000918 protionamide Drugs 0.000 claims abstract 4
- 229960005206 pyrazinamide Drugs 0.000 claims abstract 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims abstract 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims abstract 4
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims abstract 4
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims abstract 4
- 229960000885 rifabutin Drugs 0.000 claims abstract 4
- 238000005550 wet granulation Methods 0.000 claims abstract 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract 2
- 229920002261 Corn starch Polymers 0.000 claims abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract 2
- 229920000881 Modified starch Polymers 0.000 claims abstract 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract 2
- 244000061456 Solanum tuberosum Species 0.000 claims abstract 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract 2
- 235000021355 Stearic acid Nutrition 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims abstract 2
- 229940121383 antituberculosis agent Drugs 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 claims abstract 2
- 239000011248 coating agent Substances 0.000 claims abstract 2
- 238000000576 coating method Methods 0.000 claims abstract 2
- 239000003086 colorant Substances 0.000 claims abstract 2
- 239000008120 corn starch Substances 0.000 claims abstract 2
- 229960000913 crospovidone Drugs 0.000 claims abstract 2
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 238000001035 drying Methods 0.000 claims abstract 2
- 239000008187 granular material Substances 0.000 claims abstract 2
- 239000004615 ingredient Substances 0.000 claims abstract 2
- 239000008101 lactose Substances 0.000 claims abstract 2
- 239000000314 lubricant Substances 0.000 claims abstract 2
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims abstract 2
- 238000000465 moulding Methods 0.000 claims abstract 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 2
- 229920001592 potato starch Polymers 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000011734 sodium Substances 0.000 claims abstract 2
- 229910052708 sodium Inorganic materials 0.000 claims abstract 2
- 239000008117 stearic acid Substances 0.000 claims abstract 2
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
1. Комбинированное противотуберкулезное средство, включающее терапевтически эффективное количество действующего начала, в качестве которого содержит комбинацию пиразинамида, протионамида, пиридоксина гидрохлорида, отличающееся тем, что дополнительно в качестве основного компонента содержит рифабутин при следующем соотношении основных компонентов, мас.%: ! рифабутин - 4,40-18,5 ! пиразинамид - 35,53-56,50 ! протионамид - 1,52-11,10 ! пиридоксина гидрохлорид - 0,8-1,30. ! 2. Противотуберкулезное средство по п.1, отличающееся тем, что оно выполнено в форме таблетки. ! 3. Противотуберкулезное средство по п.2, отличающееся тем, что оно содержит в качестве вспомогательных веществ кремния диоксид коллоидный, крахмал прежелатинизированный, крахмал картофельный и/или кукурузный, кроссповидон, лактозу, стеариновую кислоту и/или ее соли, поливинлпирролидон среднемолекулярный, карбоксиметилкрахмал натрия, магния гидросиликат, целлюлоза микрокристаллическая, различные красители, ароматизаторы и/или вкусовые добавки. ! 4. Противотуберкулезное средство по п.2 или 3, отличающееся тем, что оно имеет оболочку. ! 5. Способ получения комбинированного противотуберкулезного средства, включающий влажную грануляцию, добавление к сухим гранулам лубриканта, формование окончательной смеси ингредиентов с образованием лекарственной формы заданной конфигурации и размера и, при необходимости, нанесение оболочки, отличающийся тем, что каждое активное вещество/каждый основной компонент проходит собственную стадию влажной грануляции и сушки после чего смешивается и таблетируется. 1. Combined anti-tuberculosis drug, comprising a therapeutically effective amount of the active principle, which contains a combination of pyrazinamide, protionamide, pyridoxine hydrochloride, characterized in that it additionally contains rifabutin in the following ratio of the main components, wt.%:! rifabutin - 4.40-18.5! pyrazinamide - 35.53-56.50! protionamide - 1.52-11.10! pyridoxine hydrochloride - 0.8-1.30. ! 2. The anti-tuberculosis drug according to claim 1, characterized in that it is made in the form of a tablet. ! 3. The anti-tuberculosis agent according to claim 2, characterized in that it contains colloidal dioxide, pregelatinized starch, potato and / or corn starch, crospovidone, lactose, stearic acid and / or its salts, polyvinylpyrrolidone sodium molecular weight, carboxyme , magnesium hydrosilicate, microcrystalline cellulose, various colorants, flavors and / or flavors. ! 4. The anti-tuberculosis drug according to claim 2 or 3, characterized in that it has a shell. ! 5. A method of producing a combined anti-tuberculosis drug, including wet granulation, adding a lubricant to the dry granules, molding the final mixture of ingredients with the formation of a dosage form of a given configuration and size and, if necessary, applying a coating, characterized in that each active substance / each main component passes own stage of wet granulation and drying, after which it is mixed and tableted.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008147737/15A RU2431487C2 (en) | 2008-12-03 | 2008-12-03 | Combined antituberculous drug and method for preparing thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008147737/15A RU2431487C2 (en) | 2008-12-03 | 2008-12-03 | Combined antituberculous drug and method for preparing thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008147737A true RU2008147737A (en) | 2010-06-10 |
| RU2431487C2 RU2431487C2 (en) | 2011-10-20 |
Family
ID=42681249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008147737/15A RU2431487C2 (en) | 2008-12-03 | 2008-12-03 | Combined antituberculous drug and method for preparing thereof |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2431487C2 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2155032C1 (en) * | 1999-03-01 | 2000-08-27 | Пятигорская государственная фармацевтическая академия | Method of preparing medicinal form with anti-inflammatory symptomatic effect |
| UA67626A (en) * | 2003-11-27 | 2004-06-15 | F H Yanovskyi Inst Of Phthisia | Method for treating patients with destructive pulmonary tuberculosis |
| RU2247560C1 (en) * | 2003-12-29 | 2005-03-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Composite formulation with antituberculous activity |
| RU2320337C1 (en) * | 2006-06-09 | 2008-03-27 | Федеральное государственное унитарное предприятие "Государственный научный центр по антибиотикам" | Method for preparing rifabutin-containing antibacterial composition |
| RU2327459C1 (en) * | 2007-06-26 | 2008-06-27 | Евгений Сергеевич Северин | Antimicrobial medicinal agent, method of production of directional medicinal agent containig nanoparticles |
| RU2384334C2 (en) * | 2008-04-15 | 2010-03-20 | Государственное Общеобразовательное Учреждение высшего профессионального образования "Пятигорская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" | Multicomponent composition with anti-tuberculosis effect |
-
2008
- 2008-12-03 RU RU2008147737/15A patent/RU2431487C2/en active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2431487C2 (en) | 2011-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703513B (en) | Compound sustained-release preparation of aspirin and clopidogrel or pharmaceutically acceptable salt thereof | |
| JP6814886B2 (en) | A novel formulation containing a benzimidazole derivative | |
| CN104661649A (en) | A solid oral pharmaceutical formulation containing ticagrelor | |
| RU2014119866A (en) | SOLID DOSED FORMS (S) -ETHYL 2-AMINO-3- (2-AMINO-6 (R) -1- (4-CHLOR-2- (3-METHYL-1H-PYRAZOL-1-IL) Phenyl) -2 , 2,2-trifluoroethoxy) pyrimidine-4-yl) phenyl) propanoate | |
| RU2480240C2 (en) | Controlled release composition for preparing prolonged release preparation containing udenafil | |
| JP2010120959A5 (en) | ||
| JP2014218523A5 (en) | ||
| RU2008147737A (en) | ANTUBERCULOSIS DRUG AND METHOD FOR ITS PRODUCTION | |
| CN102846573B (en) | Silibinin double-layer slow-release tablets and preparation method thereof | |
| JP2013203690A (en) | Intraorally disintegrating tablet and method for producing the same | |
| WO2011161689A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| JP7274825B2 (en) | Tablet and its manufacturing method | |
| RU2020115172A (en) | PHARMACEUTICAL COMPOSITION CONTAINING QUINOLINE DERIVATIVE | |
| JP2017530137A (en) | Solid pharmaceutical composition comprising amlodipine and losartan | |
| RU2018128416A (en) | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION INCLUDING A QUINOLINE DERIVATIVE OR ITS SALT | |
| RU2013130801A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES OF JOINT AND BONE TISSUES | |
| CN103006611B (en) | Omeprazole enteric bilayer slow-release tablet | |
| JP2019001782A (en) | Bilayer tablet | |
| JP2018065752A (en) | Silodosin-containing pharmaceutical composition and method for producing the same | |
| WO2019064468A1 (en) | Orally disintegrating tablet | |
| KR101310099B1 (en) | Controlled-release tablet containing aceclofenac | |
| RU2009139656A (en) | PROLONGED PHARMACEUTICAL COMPOSITION, MEDICINAL FORM AND METHOD OF ITS PRODUCTION (OPTIONS) | |
| JP2017014151A (en) | Dry coated tablet containing silodosin with improved light stability | |
| RU2006145311A (en) | SOLID PHARMACEUTICAL COMPOSITION | |
| RU2286779C2 (en) | Pelleted pharmaceutical composition with diuretic and antihypertension properties and method for production thereof |